This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Aetiology

Authoring team

Achalasia involves degeneration of the myenteric plexus and vagus nerve fibres of the lower oesophageal sphincter (1):

  • neurological defect involving the ganglion cells of Auerbach's myenteric plexus in the lower oesophageal sphincter and oesophageal body
  • abnormalities in the vagal dorsal motor nucleus, the nucleus ambiguous, and in the smooth muscle of the oesophagus.

The damaging agent has been variously hypothesised as a neurotoxic virus, an autoimmune process, and a genetic predisposition (1).

Secondary achalasia can be seen in:

  • Chagas' disease caused by Trypanosoma cruzi
  • gastric carcinoma that results in oesophageal infiltration
  • eosinophilic gastroenteritis
  • lymphoma
  • neurodegenerative disorders
  • viral infection

At its most severe, aperistalsis occurs in the lower two thirds of the oesophagus with normal peristalsis above it:

  • food accumulates in the oesophagus which becomes dilated and atonic
  • prolonged transit time may be a factor in the increased incidence of malignancy with achalasia - in up to 5% of cases.

Reference:

(1) Momodu II, Wallen JM. Achalasia. [Updated 2021 Aug 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan- Available from: https://www.ncbi.nlm.nih.gov/books/NBK519515/ - article-17083.s4 (accessed 21 January 2022)


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.